Key Points Moderna’s personalized cancer vaccine candidate, intismeran autogene, significantly reduced the risk of melanoma recurrence in a Phase 3 trial, a first for a personalized cancer vaccine.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.
